Anandamide enhances IL-10 production in activated microglia by targeting CB2 receptors: Roles of ERK1/2, JNK, and NF-κB

GLIA

Volumn 58, Issue 2, 2010, Pages 135-147

  Correa, Fernando ^a   Hernangómez, Miriam ^a   Mestre, Leyre ^a   Loría, Frida ^a   Spagnolo, Alessandra ^a   Docagne, Fabian ^a,b   Di Marzo, Vicenzo ^c   Guaza, Carmen ^a  

^a INSTITUTO CAJAL   (Spain)

^b GIP CYCERON   (France)

^c CNR   (Italy)

Author keywords

Anandamide; CB2 receptor; Endocannabinoid system; IL 10; Microglia; Splenocytes

Indexed keywords

ANANDAMIDE; CANNABINOID 2 RECEPTOR; GAMMA INTERFERON; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME INHIBITION; IMMUNOMODULATION; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SPLEEN CELL; TH1 CELL;

ANIMALS; ARACHIDONIC ACIDS; CELL LINE; CELLS, CULTURED; I-KAPPA B PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-23; LIPOPOLYSACCHARIDES; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; PHOSPHORYLATION; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB2;

EID: 73149113054     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20907     Document Type: Article

References (60)

1. Agrawal A, Dillon S, Denning TL, Pulendran B. 2006. ERK1-/- mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J Immunol 176:5788-5796.
2. Arévalo-Martín A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. 2003. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23:2511-2516.
3. 2 cannabinoid receptors as an emerging target for demyelinating diseases: From neuroimmune interactions to cell replacement strategies. Br J Pharmacol 153:216-225.
4. Aste-Amezaga M, Ma X, Sartori A, Trinchieri G. 1998. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol 160:5936-5944.
5. 2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 27:2396-2402.
6. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. 2006. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441:235-238.
7. Bisogno T, Melck D, De Petrocellis L, Bobrov MYu, Gretskaya NM, Bezuglov VV, Sitachitta N, Gerwick WH, Di Marzo V. 1998. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 248:515-522.
8. Bogdan C, Vodovotz Y, Nathan C. 1991. Macrophage deactivation by interleukin 10. J Exp Med 174:1549-1555.
9. Cabral GA, Marciano-Cabral F. 2005. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol 78:1192-1197.
10. Cabranes A, Venderoka K, de Lago E, Fezza F, Sanchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, Fernandez-Ruiz J. 2005. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis Neurobiol Dis 20:207-217.
11. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA. 2002. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Inmunopharmacol 2:69-82.
12. Carter AB, Hunninghake GW. 2000. A constitutive active MEK ERK pathway negatively regulates NF-kappa B-dependent gene expression by modulating TATA-binding protein phosphorylation. J Biol Chem 275:27858-27864.
13. Cao S, Liu J, Chesi M, Bergsagel PL, Ho IC, Donnelly RP, Ma X. 2002. Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. J Immunol 169:5715-5725.
14. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, De Chiara V, Battistini L, Bernardi G, Bernardini S, Martino G, Macarrone M. 2007. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 1093:1-11.
15. Chen BC, Chang YS, Kang JC, Hsu MJ, Sheu JR, Chen TL, Teng CM, Lin CH. 2004. Peptidoglycan induces nuclear factor-kappaB activation and cyclooxygenase-2 expression via Ras, Raf-1, and ERK in RAW 2647 macrophages. J Biol Chem 279:20889-20897.
16. Chiloeches A, Sánchez-Pacheco A, Gil-Araujo B, Aranda A, Lasa M. 2008. Thyroid hormone-mediated activation of the ERK/DUSP1 pathway augments the apoptosis of GH4C1 cells by down-regulating NF-{kappa}B activity. Mol Endocrinol 22:2466-2480.
17. Correa F, Mestre L, Docagne F, Guaza C. 2005. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 synthesis in murine macrophages: Role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 145:441-448.
18. Correa F, Docagne F, Clemente D, Mestre L, Becker C, Guaza C. 2008. Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: Possible involvement of the COX-2 metabolite prostamide E(2). Biochem J 409:761-770.
19. Correa F, Docagne F, Mestre L, Clemente D, Hernangómez M, Loría F, Guaza C. 2009. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem Pharmacol 77:86-100.
20. Croxford JL, Miller SD. 2003. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R1WIN55,212. J Clin Invest 111:1231-1240.
21. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. 1993. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178:1041-1048.
22. Docagne F, Mestre L, Loría F, Hernangómez M, Correa F, Guaza C. 2008. Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin Ther Targets 12:185-195.
23. Dong C, Davis RJ, Flavell RA. 2002. MAP kinases in the immune response. Ann Rev Immunol 20:55-72.
24. Duncan DD, Swain SL. 1994. Role of antigen-presenting cells in the polarized development of helper T cell subsets: Evidence for differential cytokine production by Th0 cells in response to antigen presentation by B cells and macrophages. Eur J Immunol 24:2506-2514.
25. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnalg H, Raine SC, Scheneider-Stock R, Nitsch R, Ulrich O. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49:67-79.
26. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A. 1991. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146:3444-3451.
27. Hanisch UK, Kettenmann H. 2007. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10:1387-1394.
28. Harizi H, Norbert G. 2004. Inhibition of IL-6, TNF-alpha, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells. Cell Immunol 228:99-109.
29. Klein TW, Newton CA. 2007. Therapeutic potential of cannabinoidbased drugs. Adv Exp Med Biol 601:395-413.
30. Lambert DM, Fowler CJ. 2005. The endocannabinoid system: Drug targets, lead compounds and potential therapeutic applications. J Med Chem 48:5059-5087.
31. Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A, Visintin C, Wiley JL, Baker D, Martin BR, Razdan RK, Di Marzo V. 2006. New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol 147:83-91.
32. Lipton HL, Dal Canto MC. 1976. Chronic neurologic disease in Theiler's virus infection of SJL/J mice. J Neurol Sci 30:201-207.
33. Liu J, Batkai S, Pacher P, Harvey-White J, Wagner JA, Cravatt BF, Gao B, Kunos G. 2003. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 278:45034-45039.
34. Liu YW, Chen CC, Tseng HP, Chang WC. 2006. Lipopolysaccharideinduced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-kappaB-induced CCAAT/enhancer-binding protein delta in mouse macrophages. Cell Signal 18:1492-1500.
35. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, Rossi FS, Woodward DF, Di Marzo V. 2007. Analgesic actions of Narachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150:766-781.
36. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. 2005. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95:437-445.
37. Martin M, Schifferle RE, Cuesta N, Vogel SN, Katz J, Michalek SM. 2003. Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J Immunol 171:717-725.
38. Masuda A, Yoshikai Y, Aiba K, Matsuguchi T. 2002. Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-Jun N-terminal kinase and p38 pathways. J Immunol 169:3801-3810.
39. Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di Marzo V. 2002. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 269:3771-3778.
40. McKenzie BS, Kastelein RA, Cua DJ. 2006. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 27:17-23.
41. Mestre L, Correa F, Arévalo-Martín A, Molina-Holgado E, Valenti M, Ortar G, Di Marzo V, Guaza C. 2005. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 92:1327-1339.
42. Molina-Holgado E, Vela JM, Arévalo-Martín A, Almazán G, Molina-Holgado F, Borrell J, Guaza C. 2002. Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 22:9742-9753.
43. Nakajima Y, Furuichim Y, Biswas KK, Hashiguchi T, Kawahara K, Yamaji K, Uchimura T, Izumi Y, Maruyama I. 2006. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. FEBS Lett 580:613-619.
44. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. 2008. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 223:114-131.
45. Ortega-Gutiérrez S, Molina-Holgado E, Arévalo-Martín A, Correa F, Viso A, López-Rodríguez ML, Di Marzo V, Guaza C. 2005. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J 19:1338-1340.
46. Peritt D, Aste-Amezaga M, Gerosa F, Paganin C, Trinchieri G. 1996. Interleukin-10 induction by IL-12: A possible modulatory mechanism? Ann NY Acad Sci 795:387-389.
47. Qian C, Jiang X, An H, Yu Y, Guo Z, Liu S, Xu H, Cao X. 2006. TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation. Blood 108:2307-2315.
48. Sancho R, Calzado MA, Di Marzo V, Appendino G, Muñoz E. 2003. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol Pharmacol 63:429-438.
49. Segal BM, Dwyer BK, Shevach EM. 1998. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 187:537-546.
50. Shnyra A, Brewington R, Alipio A, Amura C, Morrison DC. 1998. Reprogramming of lipopolysaccharide-primed macrophages is controlled by a counterbalanced production of IL-10 and IL-12. J Immunol 160:3729-3736.
51. Smith SR, Terminelli C, Denhardt G. 2000. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293:136-150.
52. Stella N. 2004. Canabinoid signalling in glial cells. Glia 48:267-277.
53. Tak PP, Firestein GS. 2001. NF-kappaB: A key role in inflammatory diseases. J Clin Invest 107:7-11.
54. Trinchieri G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133-146.
55. Trinchieri G, Kubin M, Bellone G, Cassatella MA. 1993. Cytokine cross-talk between phagocytic cells and lymphocytes: Relevance for differentiation/activation of phagocytic cells and regulation of adaptive immunity. J Cell Biochem 53:301-308.
56. Walter L, Franklin A, Witting A, Wade C, Xie Y Kunos G, Stella N. 2003. Non-psychotropic cannabinoid receptors regulate microglia cell migration. J Neurosci 23:1398-1405.
57. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. 1994. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. J Immunol 153:811-816.
58. Xia CQ, Kao KJ. 2003. Suppression of interleukin-12 production through endogenously secreted interleukin-10 in activated dendritic cells: Involvement of activation of extracellular signal-regulated protein kinase. Scand J Immunol 58:23-32.
59. Zhang P, Martin M, Michalek SM, Katz J. 2004. Role of Mitogen-Activated protein kinases and NF-B in the regulation of proinflammatory and anti-inflammatory cytokines by porphyromonas gingivalis hemagglutinin B. Infect Immun 73:3990-3998.
60. Zhou L, Nazarian AA, Smale ST. 2004. Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. Mol Cell Biol 24:2385-2396.